 |
| 15-May-13 | Reiterated |
Ladenburg Thalmann |
Buy |
$6.50 → $8.60 |
|
| 03-May-13 | Reiterated |
Deutsche Bank |
Buy |
$8 → $9 |
|
| 17-Nov-11 | Upgrade |
Oppenheimer |
Underperform → Perform |
|
|
| 17-Nov-11 | Reiterated |
UBS |
Neutral |
$7 → $4 |
|
| 14-Nov-11 | Initiated |
Collins Stewart |
Buy |
$7 |
|
| 08-Sep-11 | Resumed |
Canaccord Genuity |
Buy |
$10 |
|
| 07-Mar-11 | Upgrade |
Ladenburg Thalmann |
Sell → Neutral |
$6 → $8 |
|
| 16-Dec-10 | Initiated |
UBS |
Neutral |
$8 |
|
| 03-Nov-10 | Reiterated |
Wedbush |
Outperform |
$12 → $14 |
|
| 03-Nov-10 | Downgrade |
Ladenburg Thalmann |
Neutral → Sell |
$7.50 → $6 |
|
| 16-Apr-10 | Downgrade |
Oppenheimer |
Perform → Underperform |
|
|
| 16-Nov-09 | Downgrade |
Oppenheimer |
Outperform → Perform |
|
|
| 09-Oct-09 | Upgrade |
JMP Securities |
Mkt Perform → Mkt Outperform |
$15 |
|
| 06-Aug-09 | Reiterated |
Ladenburg Thalmann |
Neutral |
$11 → $12 |
|
| 21-Jul-09 | Upgrade |
JMP Securities |
Mkt Underperform → Mkt Perform |
|
|
| 16-Jul-09 | Reiterated |
Ladenburg Thalmann |
Neutral |
$11 |
|
| 11-Jun-09 | Downgrade |
JMP Securities |
Mkt Perform → Mkt Underperform |
|
|
| 13-May-09 | Downgrade |
JMP Securities |
Mkt Outperform → Mkt Perform |
|
|
| 30-Apr-09 | Initiated |
Leerink Swann |
Mkt Perform |
|
|
| 20-Apr-09 | Reiterated |
Oppenheimer |
Outperform |
$7 → $13 |
|
|
|
| 21-May-13 06:28PM | Cadence's Management Presents at UBS Global Healthcare Conference (Transcript) at Seeking Alpha |
| 16-May-13 08:17AM | Cadence Pharmaceuticals' CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript) at Seeking Alpha |
| 14-May-13 11:53PM | 8 Stocks Under $10 Trending Sharply Higher at TheStreet +5.03% |
| 13-May-13 05:38AM | SmithOnStocks Opines On Recent Biotech News at Seeking Alpha |
| 10-May-13 01:04PM | CADENCE PHARMACEUTICALS INC Financials EDGAR Online Financials |
| 08-May-13 04:00PM | Cadence Pharmaceuticals To Present At Three Investment Conferences During The Month Of May 2013 PR Newswire |
| 06-May-13 12:55PM | Narrower-than-Expected Loss at Cadence Zacks |
| 07:26AM | Cadence Pharmaceuticals: Ofirmev Launch Is Strong; Resolution Of Patent Issues Could Be Soon at Seeking Alpha |
| 03-May-13 09:19AM | CADENCE PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report EDGAR Online |
| 02-May-13 09:08PM | Cadence Pharmaceuticals, Inc. CEO Discuses Q1 2013 Results - Earnings Call Transcript at Seeking Alpha |
| 04:00PM | Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results PR Newswire |
| 09:10AM | CADENCE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online |
| 07:07AM | Q1 2013 Cadence Pharmaceuticals, Inc. Earnings Release - Time Not Supplied CCBN |
| 29-Apr-13 11:02AM | Brian Skorney, Senior Analyst at Robert W. Baird & Co., Interviews with The Wall Street Transcript: FDA Approvals Accelerate and Opportunities Arise in Hepatitis C Market Wall Street Transcript |
| 25-Apr-13 04:00PM | Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss First Quarter 2013 Financial Results On May 2, 2013 PR Newswire |
| 16-Apr-13 02:58PM | 4 Health Care Stocks Under $10 to Watch at TheStreet |
| 06-Apr-13 12:12PM | Should You Bet on These Hot Healthcare Stocks? at Motley Fool |
| 28-Mar-13 01:23PM | Cadence Is Tiring Out And Generic Risks Suggest Taking Profit at Seeking Alpha |
| 21-Mar-13 01:26PM | 5 Stocks Under $10 Triggering Breakouts at TheStreet +8.35% |
| 18-Mar-13 04:53PM | Good News for Cadence Pharma Zacks |
| 15-Mar-13 04:11PM | CADENCE PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online |
| 14-Mar-13 04:00PM | Cadence Pharmaceuticals Appoints Stephen L. Newman, M.D., to its Board of Directors PR Newswire |
| 01:04PM | CADENCE PHARMACEUTICALS INC Financials EDGAR Online Financials |
| 12-Mar-13 02:12PM | Narrower-Than-Expected Loss at CADX in 4Q Zacks |
| 09:07AM | InPlay: Cadence Pharma announces the availability of OFIRMEV (acetaminophen) injection through the VA National Formulary Briefing.com |
| 08:00AM | Cadence Pharmaceuticals Announces the Availability of OFIRMEV® (acetaminophen) Injection through the VA National Formulary PR Newswire |
| 11-Mar-13 12:32PM | Cadence: Potential Near-Term Catalyst For The Stock at Seeking Alpha |
| 09-Mar-13 08:04PM | New Star Analyst Rankings for Cadence Pharmaceuticals, Inc. StarMine |
| 08-Mar-13 08:02PM | New Star Analyst Rankings for Cadence Pharmaceuticals, Inc. StarMine |
| 05:00PM | CADENCE PHARMACEUTICALS INC Files SEC form 10-K, Annual Report EDGAR Online |
| 10:39AM | Cadence Pharmaceuticals Beats on Both Top and Bottom Lines at Motley Fool |
| 07-Mar-13 12:00PM | Cadence Pharmaceuticals CEO discusses Q4 2012 Results - Earnings Call Transcript at Seeking Alpha |
| 07:41AM | CADENCE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online |
| 07:30AM | Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results PR Newswire |
| 07:07AM | Q4 2012 Cadence Pharmaceuticals, Inc. Earnings Release - Time Not Supplied CCBN |
| 06:21AM | Cadence announces supply agreement with Laboratorios Grifols theflyonthewall.com |
| 01:14AM | InPlay: Cadence Pharma announces strategic plan to secure long-term manufacture and supply of OFIRMEV injection Briefing.com |
| 06-Mar-13 08:23PM | Cadence Pharmaceuticals Announces Strategic Plan to Secure Long-Term Manufacture and Supply of OFIRMEV® (acetaminophen) Injection PR Newswire |
| 28-Feb-13 05:01PM | CADENCE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and EDGAR Online |
| 04:15PM | Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Fourth Quarter And Full Year 2012 Financial Results On March 7, 2013 PR Newswire |
| 27-Feb-13 04:08PM | Optimer Consider Strategic Alternatives as CEO Steps Down at Bloomberg |
| 12:29PM | Optimer Consider Strategic Alternatives as CEO Steps Down at Bloomberg |
| 10:42AM | Optimer Consider Strategic Alternatives as CEO Steps Down at Bloomberg |
| 26-Feb-13 04:00PM | Cadence Pharmaceuticals' CEO Ted Schroeder To Present At The Cowen & Company 33rd Annual Health Care Conference In Boston On March 5, 2013 PR Newswire |
| 06-Feb-13 05:32PM | Cadence Pharmaceuticals' CEO Ted Schroeder To Present At The Leerink Swann Global Healthcare Conference In New York City On February 13, 2013 PR Newswire |
| 25-Jan-13 05:48PM | Cadence Forecasts Ofirmev Sales Zacks |
| 10:18AM | Rockwell Automation SVP Sells 34K Shares and 4 Insider Sales to Follow at Wall St. Cheat Sheet |
| 23-Jan-13 02:39PM | Cadence Management Guides To A Near Doubling Of Ofirmev Sales In 2013 at Seeking Alpha |
| 12:06PM | Cadence Pharma boosts 4Q sales outlook for Ofirmev AP |
| 07:35AM | InPlay: Cadence Pharma sees Q4 net product rev from OFIRMEV above ests, FY13 in-line Briefing.com |
| 07:30AM | Cadence Pharmaceuticals Estimates Fourth Quarter 2012 Net Product Revenue and Provides Full Year 2013 Revenue Guidance PR Newswire |
| 21-Jan-13 08:20AM | Major Revenue Losses From Patent Expirations Forces Big Pharma Companies to Look to the Biotech Industry for Replacements Marketwire |
| 11-Jan-13 05:03PM | The Medicines Co. Acquires Incline Zacks |
| 09-Jan-13 10:11AM | Could Cubist be targeting Cempra for an acquisition? at bizjournals.com |
| 08-Jan-13 01:58PM | Analysts: Cubist needs to buy another drug company at bizjournals.com |
| 10:05AM | Cubist Pharmaceuticals Deal Seen Sales Ticket: Real M&A at Bloomberg |
| 10:05AM | Cubist Pharmaceuticals Deal Seen Sales Ticket: Real M&A at Bloomberg |
| 07-Jan-13 06:50PM | Cubist Pharmaceuticals Deal Seen Sales Ticket: Real M&A at Bloomberg |
| 09:16AM | CADENCE PHARMACEUTICALS INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Other Events EDGAR Online |
| 04-Jan-13 10:22AM | Has Perrigo Become the Perfect Stock? at Motley Fool |
| 21-Dec-12 02:00PM | Cadence Pharmaceuticals: Sentiment Is Shifting From Bearish To Bullish at Seeking Alpha |
| 18-Dec-12 08:26AM | 8 Stocks Under $5 On Winning Streaks at Seeking Alpha |
| 12-Dec-12 10:42AM | CADX To Receive $14.5M Or $0.15/Share In Non-Dilutive Funds at Seeking Alpha +5.63% |
| 09:20AM | Medicines Co to spend $300 million to boost hospital products line at Reuters |
| 09:17AM | UPDATE 1-Medicines Co to spend $300 mln to boost hospital products line at Reuters |
| 07:06AM | CADENCE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material EDGAR Online |
| 07:04AM | InPlay: Cadence Pharma announces termination of option agreement to acquire Incline Therapeutics Briefing.com |
| 07:04AM | Cadence Pharmaceuticals Announces Termination of Option Agreement to Acquire Incline Therapeutics, Inc. PR Newswire |
| 06-Dec-12 01:59PM | Cadence Pharmaceuticals' CEO Hosts Analyst and Investor Day Conference (Transcript) at Seeking Alpha |
| 12:14PM | Cadence Pharmaceuticals Investor/Analyst Day Highlights Strong Ofirmev Growth Trends at Seeking Alpha |
| 11:56AM | CADENCE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online |
| 07:01AM | CADENCE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fina EDGAR Online |
| 03-Dec-12 05:54PM | Perrigo Settles Patent Litigation Zacks |
| 30-Nov-12 10:50PM | 3 Humongous Health-Care Stocks This Week at Motley Fool |
| 10:30AM | Cadence upgraded at Ladenburg theflyonthewall.com |
| 29-Nov-12 06:00AM | [video] Stocks Under $5: Discount Drug Name at TheStreet +11.96% |
| 28-Nov-12 04:50PM | Cadence and Perrigo settle patent dispute AP |
| 04:00PM | Cadence Pharmaceuticals to Host Analyst and Investor Day PR Newswire |
| 02:56PM | Cadence Pharmaceutical's Patent Settlement Bolsters My Buy Rating at Seeking Alpha |
| 08:45AM | Perrigo confirms settlement of generic version of Ofirmev injection theflyonthewall.com |
| 07:28AM | CADENCE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement EDGAR Online |
| 07:03AM | InPlay: Cadence Pharma announces settlement of OFIRMEV injection patent litigation with Perrigo Company (PRGO) Briefing.com |
| 07:00AM | Cadence Pharmaceuticals Announces Settlement of OFIRMEV® (Acetaminophen) Injection Patent Litigation with Perrigo Company PR Newswire |
| 21-Nov-12 04:00PM | Cadence Pharmaceuticals' CEO Ted Schroeder To Present At The Piper Jaffray 24th Annual Healthcare Conference In New York City On November 28, 2012 PR Newswire |
| 19-Nov-12 08:30AM | Higher Rate of FDA New Drug Approvals a Major Factor in Biotech Industry's Success in 2012 Marketwire +5.30% |
| 08:20AM | Higher Rate of FDA New Drug Approvals a Major Factor in Biotech Industry's Success in 2012 Marketwire |
| 13-Nov-12 01:08PM | Cadence Pharmaceuticals Hits Estimates in Solid Quarter at Motley Fool |
| 10-Nov-12 01:04PM | CADENCE PHARMACEUTICALS INC Financials EDGAR Online Financials |
| 06-Nov-12 04:26PM | CADENCE PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report EDGAR Online |
| 05-Nov-12 08:39PM | Cadence Pharmaceuticals' CEO Discusses Q3 2012 Results - Earnings Call Transcript at Seeking Alpha |
| 04:22PM | CADENCE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online |
| 04:00PM | Cadence Pharmaceuticals Reports Third Quarter 2012 Financial Results PR Newswire |
| 07:07AM | Q3 2012 Cadence Pharmaceuticals, Inc. Earnings Release - After Market Close CCBN |
| 29-Oct-12 04:00PM | Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Third Quarter 2012 Financial Results On November 5, 2012 PR Newswire |
| 09-Oct-12 02:18PM | 5 Highly Liquid Small Cap Stocks Projected For Strong Growth at Seeking Alpha |
| 20-Sep-12 12:57PM | Strong August Results Bolster Confidence In Success Of Cadence Pharma's Ofirmev Launch at Seeking Alpha |
| 18-Sep-12 01:36PM | AcelRX hires former UPMC physician at bizjournals.com |
| 30-Aug-12 03:40PM | Cadence falls on analyst downgrade at MarketWatch -9.95% |
| 03:23PM | Why the Dow Is Falling Today at Motley Fool |
| 10:41AM | 6 Liquid Small-Cap Healthcare Stocks Projected For Strong Growth at Seeking Alpha |
|
|
| Cadence Pharmaceuticals, Inc., a biopharmaceutical company, focuses on acquiring, in-licensing, developing, and commercializing proprietary product candidates for use in the hospital setting primarily in the United States and Canada. It holds rights to OFIRMEV injection, a proprietary intravenous formulation of acetaminophen for the management of mild to moderate pain, moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever in adults and children. OFIRMEV is targeted at anesthesiologists, surgeons, certified registered nurse anesthetists, emergency medicine physicians, intensivists, internists, hospitalists, obstetricians, and other physicians throughout the hospital, as well as hospital-based pharmacists. The company in-licenses rights to OFIRMEV from Bristol-Myers Squibb Company, which sells intravenous acetaminophen in Europe and other markets for the treatment of acute pain and fever under the Perfalgan brand name. Cadence Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Domain Partners VI, L.P. | 10% Owner | Apr 15 | Sale | 6.62 | 71,578 | 473,846 | 7,313,241 | Apr 17 05:14 PM | | DOMAIN PARTERS VII L P | 10% Owner | Apr 15 | Sale | 6.62 | 23,210 | 153,650 | 2,371,190 | Apr 17 05:27 PM | | Domain Partners VI, L.P. | 10% Owner | Apr 10 | Sale | 6.72 | 4,832 | 32,471 | 7,384,819 | Apr 10 04:47 PM | | DOMAIN PARTERS VII L P | 10% Owner | Apr 10 | Sale | 6.72 | 1,567 | 10,530 | 2,394,400 | Apr 10 04:49 PM | | Domain Partners VI, L.P. | 10% Owner | Apr 09 | Sale | 6.71 | 35,114 | 235,615 | 7,389,651 | Apr 10 04:47 PM | | DOMAIN PARTERS VII L P | 10% Owner | Apr 09 | Sale | 6.71 | 11,386 | 76,400 | 2,395,967 | Apr 10 04:49 PM | | Domain Partners VI, L.P. | 10% Owner | Apr 08 | Sale | 6.52 | 37,676 | 245,648 | 7,424,765 | Apr 10 04:47 PM | | DOMAIN PARTERS VII L P | 10% Owner | Apr 08 | Sale | 6.52 | 12,217 | 79,655 | 2,407,353 | Apr 10 04:49 PM | | Domain Partners VI, L.P. | 10% Owner | Mar 21 | Sale | 5.35 | 13,490 | 72,172 | 7,462,441 | Mar 22 08:22 PM | | DOMAIN PARTERS VII L P | 10% Owner | Mar 21 | Sale | 5.35 | 4,374 | 23,401 | 2,419,570 | Mar 22 08:28 PM | | DP VII ASSOCIATES LP | 10% Owner | Mar 21 | Sale | 5.49 | 893 | 4,903 | 40,484 | Mar 22 06:16 PM | | DP VI Associates, L.P. | 10% Owner | Mar 21 | Sale | 5.49 | 1,743 | 9,569 | 78,369 | Mar 22 06:19 PM | | DOMAIN PARTERS VII L P | 10% Owner | Mar 20 | Sale | 5.22 | 5,510 | 28,762 | 2,423,944 | Mar 21 04:58 PM | | Domain Partners VI, L.P. | 10% Owner | Mar 20 | Sale | 5.22 | 16,995 | 88,714 | 7,475,931 | Mar 21 05:02 PM | | DP VII ASSOCIATES LP | 10% Owner | Mar 20 | Sale | 5.22 | 92 | 480 | 41,377 | Mar 21 05:10 PM | | DP VI Associates, L.P. | 10% Owner | Mar 20 | Sale | 5.22 | 182 | 950 | 80,112 | Mar 21 05:13 PM | | DOMAIN PARTERS VII L P | 10% Owner | Mar 19 | Sale | 5.19 | 7,925 | 41,131 | 2,429,454 | Mar 21 04:58 PM | | Domain Partners VI, L.P. | 10% Owner | Mar 19 | Sale | 5.19 | 24,442 | 126,854 | 7,492,926 | Mar 21 05:02 PM | | DP VII ASSOCIATES LP | 10% Owner | Mar 19 | Sale | 5.19 | 134 | 695 | 41,469 | Mar 21 05:10 PM | | DP VI Associates, L.P. | 10% Owner | Mar 19 | Sale | 5.19 | 261 | 1,355 | 80,294 | Mar 21 05:13 PM | | DOMAIN PARTERS VII L P | 10% Owner | Mar 18 | Sale | 5.16 | 8,020 | 41,383 | 2,437,379 | Mar 19 04:34 PM | | Domain Partners VI, L.P. | 10% Owner | Mar 18 | Sale | 5.16 | 24,736 | 127,638 | 7,517,368 | Mar 19 04:39 PM | | DP VII ASSOCIATES LP | 10% Owner | Mar 18 | Sale | 5.16 | 135 | 697 | 41,603 | Mar 19 04:43 PM | | DP VI Associates, L.P. | 10% Owner | Mar 18 | Sale | 5.16 | 265 | 1,367 | 80,555 | Mar 19 04:47 PM | | DOMAIN PARTERS VII L P | 10% Owner | Mar 15 | Sale | 5.28 | 9,636 | 50,878 | 2,445,399 | Mar 19 04:34 PM | | Domain Partners VI, L.P. | 10% Owner | Mar 15 | Sale | 5.28 | 29,719 | 156,916 | 7,542,104 | Mar 19 04:39 PM | | DP VII ASSOCIATES LP | 10% Owner | Mar 15 | Sale | 5.28 | 163 | 861 | 41,738 | Mar 19 04:43 PM | | DP VI Associates, L.P. | 10% Owner | Mar 15 | Sale | 5.28 | 318 | 1,679 | 80,820 | Mar 19 04:47 PM | | DP VII ASSOCIATES LP | 10% Owner | Mar 14 | Sale | 5.36 | 85 | 456 | 41,901 | Mar 15 04:59 PM | | Domain Partners VI, L.P. | 10% Owner | Mar 14 | Sale | 5.36 | 15,480 | 82,973 | 7,571,823 | Mar 15 04:57 PM | | DOMAIN PARTERS VII L P | 10% Owner | Mar 14 | Sale | 5.36 | 5,020 | 26,907 | 2,455,035 | Mar 15 04:55 PM | | DP VI Associates, L.P. | 10% Owner | Mar 14 | Sale | 5.36 | 166 | 890 | 81,138 | Mar 15 05:02 PM | | DP VI Associates, L.P. | 10% Owner | Mar 13 | Sale | 5.40 | 256 | 1,382 | 81,304 | Mar 15 05:02 PM | | DP VII ASSOCIATES LP | 10% Owner | Mar 13 | Sale | 5.40 | 131 | 707 | 41,986 | Mar 15 04:59 PM | | Domain Partners VI, L.P. | 10% Owner | Mar 13 | Sale | 5.40 | 23,848 | 128,779 | 7,587,303 | Mar 15 04:57 PM | | DOMAIN PARTERS VII L P | 10% Owner | Mar 13 | Sale | 5.40 | 7,733 | 41,758 | 2,460,055 | Mar 15 04:55 PM | | DP VI Associates, L.P. | 10% Owner | Mar 12 | Sale | 5.38 | 210 | 1,130 | 81,560 | Mar 13 08:40 PM | | DP VII ASSOCIATES LP | 10% Owner | Mar 12 | Sale | 5.38 | 107 | 576 | 42,117 | Mar 13 08:38 PM | | Domain Partners VI, L.P. | 10% Owner | Mar 12 | Sale | 5.38 | 19,569 | 105,281 | 7,611,151 | Mar 13 08:36 PM | | DOMAIN PARTERS VII L P | 10% Owner | Mar 12 | Sale | 5.38 | 6,346 | 34,141 | 2,467,788 | Mar 13 08:33 PM | | DP VI Associates, L.P. | 10% Owner | Mar 11 | Sale | 5.34 | 136 | 726 | 81,770 | Mar 13 08:40 PM | | DP VII ASSOCIATES LP | 10% Owner | Mar 11 | Sale | 5.34 | 70 | 374 | 42,224 | Mar 13 08:38 PM | | Domain Partners VI, L.P. | 10% Owner | Mar 11 | Sale | 5.34 | 12,700 | 67,818 | 7,630,720 | Mar 13 08:36 PM | | DOMAIN PARTERS VII L P | 10% Owner | Mar 11 | Sale | 5.34 | 4,118 | 21,990 | 2,474,134 | Mar 13 08:33 PM | | DP VI Associates, L.P. | 10% Owner | Mar 08 | Sale | 5.32 | 171 | 910 | 81,906 | Mar 11 06:39 PM | | DP VII ASSOCIATES LP | 10% Owner | Mar 08 | Sale | 5.32 | 88 | 468 | 42,294 | Mar 11 06:35 PM | | DOMAIN PARTERS VII L P | 10% Owner | Mar 08 | Sale | 5.32 | 5,154 | 27,419 | 2,478,252 | Mar 11 06:29 PM | | DP VI Associates, L.P. | 10% Owner | Mar 07 | Sale | 5.22 | 420 | 2,192 | 82,077 | Mar 11 06:39 PM | | DP VII ASSOCIATES LP | 10% Owner | Mar 07 | Sale | 5.22 | 215 | 1,122 | 42,382 | Mar 11 06:35 PM | | DOMAIN PARTERS VII L P | 10% Owner | Mar 07 | Sale | 5.22 | 12,701 | 66,299 | 2,483,406 | Mar 11 06:29 PM | | Domain Partners VI, L.P. | 10% Owner | Mar 06 | Sale | 5.06 | 11,841 | 59,915 | 7,698,480 | Mar 07 06:22 PM | | DOMAIN PARTERS VII L P | 10% Owner | Mar 06 | Sale | 5.06 | 3,839 | 19,425 | 2,496,107 | Mar 07 06:19 PM | | DP VI Associates, L.P. | 10% Owner | Mar 06 | Sale | 5.06 | 127 | 643 | 82,497 | Mar 07 06:15 PM | | DP VII ASSOCIATES LP | 10% Owner | Mar 06 | Sale | 5.06 | 65 | 329 | 42,597 | Mar 07 06:12 PM | | Domain Partners VI, L.P. | 10% Owner | Mar 05 | Sale | 5.01 | 12,454 | 62,395 | 7,710,321 | Mar 07 06:22 PM | | DOMAIN PARTERS VII L P | 10% Owner | Mar 05 | Sale | 5.01 | 4,039 | 20,235 | 2,499,946 | Mar 07 06:19 PM | | DP VI Associates, L.P. | 10% Owner | Mar 05 | Sale | 5.01 | 134 | 671 | 82,624 | Mar 07 06:15 PM | | DP VII ASSOCIATES LP | 10% Owner | Mar 05 | Sale | 5.01 | 69 | 346 | 42,662 | Mar 07 06:12 PM | | DP VII ASSOCIATES LP | 10% Owner | Mar 04 | Sale | 5.01 | 88 | 441 | 42,731 | Mar 05 05:18 PM | | DP VI Associates, L.P. | 10% Owner | Mar 04 | Sale | 5.01 | 170 | 852 | 82,758 | Mar 05 05:12 PM | | DOMAIN PARTERS VII L P | 10% Owner | Mar 04 | Sale | 5.01 | 5,145 | 25,776 | 2,503,985 | Mar 05 05:06 PM | | Domain Partners VI, L.P. | 10% Owner | Mar 04 | Sale | 5.01 | 15,865 | 79,484 | 7,722,775 | Mar 05 05:02 PM | | DP VII ASSOCIATES LP | 10% Owner | Mar 01 | Sale | 5.01 | 130 | 651 | 42,819 | Mar 05 05:18 PM | | DP VI Associates, L.P. | 10% Owner | Mar 01 | Sale | 5.01 | 253 | 1,268 | 82,928 | Mar 05 05:12 PM | | DOMAIN PARTERS VII L P | 10% Owner | Mar 01 | Sale | 5.01 | 7,635 | 38,251 | 2,509,130 | Mar 05 05:06 PM | | Domain Partners VI, L.P. | 10% Owner | Mar 01 | Sale | 5.01 | 23,548 | 117,975 | 7,738,640 | Mar 05 05:02 PM | | Domain Partners VI, L.P. | 10% Owner | Feb 20 | Sale | 5.01 | 6,160 | 30,862 | 7,762,188 | Feb 22 04:58 PM | | DP VII ASSOCIATES LP | 10% Owner | Feb 20 | Sale | 5.01 | 34 | 170 | 42,949 | Feb 22 04:53 PM | | DP VI Associates, L.P. | 10% Owner | Feb 20 | Sale | 5.01 | 66 | 331 | 83,181 | Feb 22 04:50 PM | | DOMAIN PARTERS VII L P | 10% Owner | Feb 20 | Sale | 5.01 | 1,998 | 10,010 | 2,516,765 | Feb 22 04:46 PM | | DP VII ASSOCIATES LP | 10% Owner | Feb 19 | Sale | 5.02 | 171 | 858 | 42,983 | Feb 20 04:55 PM | | DOMAIN PARTERS VII L P | 10% Owner | Feb 19 | Sale | 5.02 | 10,076 | 50,582 | 2,518,763 | Feb 20 04:52 PM | | DP VI Associates, L.P. | 10% Owner | Feb 19 | Sale | 5.02 | 334 | 1,677 | 83,247 | Feb 20 04:47 PM | | Domain Partners VI, L.P. | 10% Owner | Feb 19 | Sale | 5.02 | 31,075 | 155,997 | 7,768,348 | Feb 20 04:43 PM | | DP VII ASSOCIATES LP | 10% Owner | Feb 15 | Sale | 5.00 | 51 | 255 | 43,154 | Feb 20 04:55 PM | | DOMAIN PARTERS VII L P | 10% Owner | Feb 15 | Sale | 5.00 | 2,967 | 14,835 | 2,528,839 | Feb 20 04:52 PM | | DP VI Associates, L.P. | 10% Owner | Feb 15 | Sale | 5.00 | 99 | 495 | 83,581 | Feb 20 04:47 PM | | Domain Partners VI, L.P. | 10% Owner | Feb 15 | Sale | 5.00 | 9,148 | 45,740 | 7,799,423 | Feb 20 04:43 PM | | DP VII ASSOCIATES LP | 10% Owner | Feb 14 | Sale | 5.01 | 51 | 256 | 43,205 | Feb 15 05:12 PM | | DP VI Associates, L.P. | 10% Owner | Feb 14 | Sale | 5.01 | 98 | 491 | 83,680 | Feb 15 05:08 PM | | DOMAIN PARTERS VII L P | 10% Owner | Feb 14 | Sale | 5.01 | 2,951 | 14,785 | 2,531,806 | Feb 15 05:03 PM | | Domain Partners VI, L.P. | 10% Owner | Feb 14 | Sale | 5.01 | 9,100 | 45,591 | 7,808,571 | Feb 15 04:57 PM | | DP VII ASSOCIATES LP | 10% Owner | Feb 13 | Sale | 5.00 | 98 | 490 | 43,256 | Feb 15 05:12 PM | | DP VI Associates, L.P. | 10% Owner | Feb 13 | Sale | 5.00 | 191 | 955 | 83,778 | Feb 15 05:08 PM | | DOMAIN PARTERS VII L P | 10% Owner | Feb 13 | Sale | 5.00 | 5,763 | 28,815 | 2,534,757 | Feb 15 05:03 PM | | Domain Partners VI, L.P. | 10% Owner | Feb 13 | Sale | 5.00 | 17,770 | 88,850 | 7,817,671 | Feb 15 04:57 PM | | Domain Partners VI, L.P. | 10% Owner | Feb 01 | Sale | 4.85 | 30,134 | 146,150 | 7,835,441 | Feb 05 06:19 PM | | DP VII ASSOCIATES LP | 10% Owner | Feb 01 | Sale | 4.85 | 164 | 795 | 43,354 | Feb 05 06:16 PM | | DP VI Associates, L.P. | 10% Owner | Feb 01 | Sale | 4.85 | 322 | 1,562 | 83,969 | Feb 05 06:14 PM | | DOMAIN PARTERS VII L P | 10% Owner | Feb 01 | Sale | 4.85 | 9,769 | 47,380 | 2,540,520 | Feb 05 06:11 PM | | DP VII ASSOCIATES LP | 10% Owner | Jan 31 | Sale | 4.71 | 314 | 1,479 | 43,518 | Feb 01 04:53 PM | | Domain Partners VI, L.P. | 10% Owner | Jan 31 | Sale | 4.71 | 57,165 | 269,247 | 7,865,575 | Feb 01 05:28 PM | | DOMAIN PARTERS VII L P | 10% Owner | Jan 31 | Sale | 4.71 | 18,537 | 87,309 | 2,550,289 | Feb 01 05:25 PM | | DP VI Associates, L.P. | 10% Owner | Jan 31 | Sale | 4.71 | 613 | 2,887 | 84,291 | Feb 01 05:22 PM | | DP VII ASSOCIATES LP | 10% Owner | Jan 30 | Sale | 5.00 | 188 | 940 | 43,832 | Feb 01 04:53 PM | | Domain Partners VI, L.P. | 10% Owner | Jan 30 | Sale | 5.00 | 34,248 | 171,240 | 7,922,740 | Feb 01 05:28 PM | | DOMAIN PARTERS VII L P | 10% Owner | Jan 30 | Sale | 5.00 | 11,105 | 55,525 | 2,568,826 | Feb 01 05:25 PM | | DP VI Associates, L.P. | 10% Owner | Jan 30 | Sale | 5.00 | 367 | 1,835 | 84,904 | Feb 01 05:22 PM | | Domain Partners VI, L.P. | 10% Owner | Jan 29 | Sale | 5.27 | 47,247 | 248,992 | 7,956,988 | Jan 30 07:25 PM | | DOMAIN PARTERS VII L P | 10% Owner | Jan 29 | Sale | 5.27 | 15,320 | 80,736 | 2,579,931 | Jan 30 07:20 PM |
|
|
|
|
|
|
